Table 2.

Change in slowing and depressive symptoms before and after L-DOPA treatment. ‘Screening’ refers to assessments performed at screening visit, ‘Week 0’ refers to pre-medication baseline, and Week 1–3 refer to assessments performed after 150mg, 300mg, and 450mg L-DOPA, respectively. Dose effects are estimated by tests of change from pre-treatment (Week 0). Effect size (ES) is calculated by scaling the mean change by the standard deviation at Week 0. HRSD=Hamilton Rating Scale for Depressive Symptoms, IDS-SR=Inventory for Depressive Symptomatology—Self Report. Subjects contributing data to this table were N=36 (Screen, Week 0, and Week 1), N=35 at Week 2, and N=33 at Week 3.

	Visit	Dose	Mean±SD	Mean change±SE	Mean change 95% CI	ES±SE	ES 95% CL	P-value
Processing speed Measures
Digit symbol	Screening		31.86±9.69					.
	Week 0	Pre-treatment	37.19±8.73					.
	Week 1	150mg	38.89±9.43	1.69±0.77	0.19,3.20	0.19±0.09	0.02,0.37	0.0271
	Week 2	300mg	41.09±8.54	3.89±0.88	2.17,5.62	0.45±0.10	0.25,0.64	<.0001
	Week 3	450mg	41.42±9.56	4.23±0.94	2.38,6.08	0.48±0.11	0.27,0.70	<.0001
Pattern comparison	Screening		24.72±5.42					.
	Week 0	Pre-treatment	25.39±5.57					.
	Week 1	150mg	26.89±4.87	1.5±0.63	0.27,2.73	0.27±0.11	0.05,0.49	0.0171
	Week 2	300mg	27.29±5.7	1.91±0.69	0.55,3.27	0.34±0.12	0.10,0.59	0.006
	Week 3	450mg	27.61±4.94	2.22±0.56	1.12,3.32	0.40±0.10	0.20,0.60	<.0001
Letter comparison	Screening		14.36±4.73					.
	Week 0	Pre-treatment	15±4.53					.
	Week 1	150mg	15.33±4.64	0.33±0.52	−0.69,1.36	0.07±0.12	−0.15,0.3	0.5248
	Week 2	300mg	15.65±4.66	0.65±0.5	−0.33,1.62	0.14±0.11	−0.07,0.36	0.194
	Week 3	450mg	15.69±4.54	0.69±0.54	−0.37,1.74	0.15±0.12	−0.08,0.38	0.2016
Processing factor (composite of DS, PC, and LC)	Screening		−2.87±7.05					.
	Week 0	Pre-treatment	−0.91±6.79					.
	Week 1	150mg	0.63±6.33	1.53±0.58	0.40,2.67	0.23±0.09	0.06,0.39	0.008
	Week 2	300mg	1.54±6.47	2.45±0.61	1.26,3.64	0.36±0.09	0.19,0.54	<.0001
	Week 3	450mg	1.85±6.72	2.76±0.59	1.60,3.91	0.41±0.09	0.24,0.58	<.0001
Gait speed measures
Single task gait speed	Screening		0.80±0.18					.
	Week 0	Pre-treatment	0.88±0.21					.
	Week 1	150mg	0.89±0.19	0.01±0.02	−0.02,0.05	0.07±0.08	−0.09,0.22	0.4066
	Week 2	300mg	0.91±0.21	0.04±0.03	−0.01,0.09	0.18±0.12	−0.06,0.42	0.1465
	Week 3	450mg	0.92±0.21	0.04±0.02	0.00,0.08	0.19±0.09	0.01,0.38	0.0369
Dual task gait speed	Screening		0.69±0.23					.
	Week 0	Pre-treatment	0.74±0.20					.
	Week 1	150mg	0.74±0.23	0.00±0.02	−0.05,0.05	0±0.12	−0.23,0.23	0.9999
	Week 2	300mg	0.80±0.24	0.06±0.03	0.01,0.12	0.32±0.15	0.03,0.62	0.0314
	Week 3	450mg	0.82±0.24	0.09±0.03	0.03,0.14	0.43±0.14	0.16,0.70	0.0018
Depression measures
Hamilton Rating Scale for Depression (24 item)	Screening		15.53±6.04					.
	Week 0	Pre-treatment	13.42±6.63					.
	Week 1	150mg	11.97±6.96	−1.44±0.94	−3.29,0.40	−0.22±0.14	−0.5,0.06	0.125
	Week 2	300mg	11.06±6.17	−2.36±1.03	−4.37,−0.35	−0.36±0.16	−0.66,−0.05	0.0216
	Week 3	450mg	10.94±6.87	−2.48±0.80	−4.05,−0.90	−0.37±0.12	−0.61,−0.14	0.002
Inventory of Depressive Symptomatology—Self Report	Screening		26.42±12.57					.
	Week 0	Pre-treatment	22.47±13.61					.
	Week 1	150mg	19.17±11.44	−3.31±1.9	−7.03,0.42	−0.24±0.14	−0.52,0.03	0.0819
	Week 2	300mg	17.57±11.71	−4.9±1.86	−8.55,−1.25	−0.36±0.14	−0.63,−0.09	0.0084
	Week 3	450mg	15.09±10.64	−7.38±1.38	−10.09,−4.67	−0.54±0.1	−0.74,−0.34	<.0001